

Freedom of Information Request

May 2019

Recognition and Referral

1. Does your Trust have a specified pathway from primary care to secondary care for inflammatory back pain in place?

Please select one of the following response options

- Yes
- No

If you answered 'yes', please give details below of the pathway and, if applicable, arrangements in place to raise awareness in primary care

t

her of the above response options apply to you, please provide more information on your local arrangements below

Diagnosis in specialist care settings

2. What is the average current waiting time to diagnosis for a patient referred with inflammatory back pain?

Please select one of the following response options

Option	Please tick here (one option only)
Less than 1 month	
1 – 2 months	
2 – 3 months	
3 – 4 months	
4 – 5 months	
5 – 6 months	
6 – 12 months	
More than 12 months	

3. Are patients with suspected axial SpA (AS) routinely referred for a full spinal MRI?

Please select one of the following response options

Option	Please tick here (one option only)
Yes	
No	

If neither of the above response options apply to you, please provide more information on your local arrangements below

Information and Support

--

4. How do you ensure patients are given information and support following their diagnosis?
Please select whichever response options apply

Option	Please tick here (tick all that apply)
Written information	
Verbal information	
Access to a helpline	
Named contact in the team	
Group educational sessions	
Other (please provide details)	

Pharmacological management of axial SpA (AS)

5. What guidance are patients with axial SpA (AS) given when deciding whether to access biologic treatment?
Please provide details of arrangements in your local area below

6.

--

In line with the NICE anti TNF guidance for ankylosing spondylitis (TA383) states that, 'Treatment with another anti TNF is recommended for people who cannot tolerate, or whose disease has not responded to, treatment with the first TNF-alpha inhibitor, or whose disease has stopped responding after an initial response', after failure with one biologic, how many other biologics will your commissioners fund a patient with axial SpA (AS) to try, including IL 17As?

Please select one of the following response options

Option	Please tick here (one option only)
None	
1	
2	
3 or more	

If none of the above response options apply to you, please provide more information on your local arrangements below

Non-pharmacological management of axial SpA

7. What proportion of adults with axial SpA (AS) are referred to a specialist physiotherapist for a structured exercise programme within your local area when first diagnosed?

Please provide details below

Flare management

8. What percentage of patients with axial SpA (AS) have a written care plan to support them with a flare?

Please provide details below

Please provide details below

Organisation of care

9. Does the Trust have a dedicated axial SpA (AS) clinic?

Please select one of the following response options

Option	Please tick here (one option only)
Yes	
No	

If neither of the above response options apply to you, please provide more information on your local arrangements below

Mental health and well being

10. Are axial SpA (AS) patients under the care of a rheumatologist offered access to psychological services?

Please select one of the following response options

Option	Please tick here (one option only)
--------	------------------------------------

Yes	
No	

/

ticked 'yes', please specify the services on offer

Information not held by UHNM